

R is selected from the group consisting of

- a) H,
- b) **PG**,

5 **PG** is an "Amine-protecting group",

LG is a leaving group,

10 wherein in step 3 a HPLC method is used, wherein the HPLC solvent or solvent mixture is part of an injectable Formulation of compound I suitable for injection into humans selected from the group consisting of ethanol, an aqueous buffer or an ethanol/aqueous buffer mixture.

15 2. A method according to claim 1, wherein **PG** is selected from the group consisting of:

- a) Boc,
- b) Trityl and
- c) 4-Methoxytrityl.

20 3. A method according to claim 1 or 2, wherein **LG** is selected from the group consisting of:

- a) Halogen and
- 25 b) Sulfonyloxy,

Halogen is chloro, bromo or iodo.

30 4. A method according to claim 3, wherein Sulfonyloxy is selected from the group consisting of:

- a) Methanesulfonyloxy,
- b) *p*-Toluenesulfonyloxy,

- c) (4-Nitrophenyl)sulfonyloxy,
- d) (4-Bromophenyl)sulfonyloxy.

5. A method according to claim 1, wherein $n = 3$ and $X = CH$.

6. A method according to claim 1, wherein $n = 3$, $X = CH$, $R = Boc$, and $LG =$ Methanesulfonyloxy.

~~7. A method according to claims 1 – 6, wherein the HPLC solvent is selected from the group consisting of ethanol, an aqueous buffer or an ethanol/aqueous buffer mixture.~~

~~87. A method according to claim 71, wherein the aqueous buffer is selected from the group consisting of sodium chloride, sodium phosphate buffer, ascorbic acid, ascorbate buffer or a mixture thereof.~~

~~98. A method according to claims 1 – 87, wherein 10-50 μ mol of a compound of Formula II is used.~~

~~109. A method according to claims 1 – 98, wherein the method is performed as a fully automated process.~~

~~110. A kit, for producing a compound of Formula I according to the method in claim 1 comprising a sealed vial containing a compound of Formula II and a sealed vial containing a solution for HPLC that can be part of an injectable Formulation of compound I suitable for injection into humans selected from the group consisting of ethanol, an aqueous buffer or an ethanol/aqueous buffer mixture.~~

~~12. A kit, according to claim 10, wherein the solution for HPLC that can be part of an injectable Formulation of compound I suitable for injections into humans is selected from the group consisting of ethanol, an aqueous buffer or an ethanol/aqueous buffer mixture.~~

~~13~~11. A kit according to claim ~~12~~10, wherein the aqueous buffer is selected from the group consisting of sodium chloride, sodium phosphate buffer, ascorbic acid, ascorbate buffer or a mixture thereof.